Studies have demonstrated that while dupilumab effectively reduces the symptoms of conditions associated with type 2 inflammation, such as asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), its impact on IgE levels is more nuanced. This evidence concerns the gene IGHE and nasal cavity polyp.